Xinhua Tokyo November 23 Mar (press blue construction) University of Tokyo researchers announced that they developed with induction-stem cells (iPS cells) manufacturing technology, and platelets in animal experiments confirmed the manufactured platelet function with bleeding.
IPS cells is strong differentiation potential of stem cells from skin cells and other somatic GM "induced" development. Cultivating such cells do not require use of human embryos, and infinite proliferation, new technology is expected to be used for mass production of platelets for transfusion.
Tokyo University Associate Professor River cane-HO's study group, led by the United States in 22 of the journal of experimental medicine magazine publishes papers that they begin with the use of human skin tissue mother cells and umbilical cord blood cells produce iPS cells, and then joined several blood cell growth factors and nutrition cell, developed to manufacture platelet of megakaryocytes, eventually produce platelets.
The researchers will produce of platelets to mice, platelet concentrate to found injured blood vessels, thrombosis, normal play the platelet function.
Researchers use and cancer-related genes cMyc efficiently manufacture Megakaryocyte and platelet production. Because of the platelets do not exist in the nucleus containing genetic information, and the other hybrid which cells nuclei can filter through exposure to radiation and removal, the application does not have the risk of malignant transformation.
Platelets are the blood cells, to prevent freezing blood, bleeding. Surgery using platelet now rely entirely on donations. The research team is ready to confirm the security of the new technology, apply it as soon as possible.
(1m1m responsible editor: gaohua)
No comments:
Post a Comment